28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Diphenylborinic acid is a strong inhibitor of serine proteases

TBA
1
PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation.

Fudan University
1
Recent advances in developing targeted protein degraders.

Hubei Polytechnic University
8
Identification of benzothiazoles as novel PCSK9 inhibitors.

Hebei Normal University
4
Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds.

Fudan University
30
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups.

Pfizer
6
Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.

Smith, Gambrell & Russell
20
Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis.

Peking Union Medical College
17
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.

Aligarh Muslim University
4
Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents.

Merck
22
Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9.

University of Montpellier
2
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.

The University of Queensland
10
Discovery of Small-Molecule CD33 Pre-mRNA Splicing Modulators.

Pfizer
18
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.

Merck
10
From methylene bridged diindole to carbonyl linked benzimidazoleindole: Development of potent and metabolically stable PCSK9 modulators.

University of Wisconsin-Madison
31
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.

Merck
6
Novel Cyclic Tetramer Compounds as PCSK9 Inhibitors for Treating Metabolic Disorders.

Lauren Mccallister
12
Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.

University of Wisconsin
8
Small molecules as inhibitors of PCSK9: Current status and future challenges.

China Pharmaceutical University
4
Small molecule modulators of PCSK9 - A literature and patent overview.

AstraZeneca
6
O'-(epoxyalkyl)tyrosines and (epoxyalkyl)phenylalanine as irreversible inactivators of serine proteases: synthesis and inhibition mechanism.

State University
46
Cereblon ligands and bifunctional compounds comprising the same

Arvinas
156
Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK)

Merck Patent
26
Highly active CSF1R inhibitor compound

Xiamen Biotime Biotechnology
56
Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Vanderbilt University
73
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor

Bristol Myers Squibb
74
Glucagon receptor modulators

Pfizer
4
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli.

National Institutes of Health